ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1314

Comparison of the Utility and Validity of Three Scoring Tools to Detect Skin Disease in Patients with Juvenile Dermatomyositis

Raquel Campanilho-Marques1, Beverley Almeida2, Katie Arnold1, Kiran Nistala3, Clarissa A Pilkington4 and Lucy R Wedderburn1, 1Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, 2Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 3Centre for Rheumatology, University College London, London, United Kingdom, 4Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Disease Activity, juvenile dermatomyositis and skin

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Lupus, Scleroderma and Myositis (ACR)

Session Type: Abstract Submissions (ACR)

Background/Purpose: Juvenile dermatomyositis (JDM) is a rare condition affecting 3 children/million/year. Muscle and skin involvement are key features. The muscle symptoms are frequently the main initial focus: formal measures (Childhood Myositis Assessment Scale – CMAS and Manual Muscle Test – MMT8) exist to routinely and accurately assess this component of the disease. However the involvement of skin, and its assessment, is a vital aspect. The abbreviated Cutaneous Assessment Tool (CAT) encompassing active skin disease and skin damage, Disease Activity Score (DAS) and Myositis Intention to Treat Activity Index (MITAX), both with skin components, have all been suggested to measure skin disease in JDM; however the optimal tool is unknown.  The aim was to compare 3 tools for assessment of skin disease in JDM and correlate them with the physician’s 10cm skin visual analogue scale (physician’s skin VAS) to define which tool best assesses skin disease.

Methods: Patients recruited to the UK JDM Cohort & Biomarker Study who fulfil Bohan-Peter criteria for JDM were included. Each patient was assessed for skin disease using the CAT, DAS, MITAX and an overall physician’s skin VAS. Markers of muscle disease (CMAS, MMT8, CK U/L), inflammatory markers (CRP mg/L and ESR mm/hr) and overall physician’s global score were also recorded. Spearman’s correlations (rs) were used to correlate categorical and continuous variables and a relationship >0.75 was considered strong. A p-value <0.05 was considered significant.

Results: Between 2012 and 2014, 67 JDM patients were assessed. 59.7% were female. The mean (±SD) age of the patients was 9.86 ±3.37 years, with mean age at diagnosis 6.59 ±3.42 years and mean disease duration of 3.26 ±3.08 years. The skin section of the DAS had the strongest correlation with the physician’s skin VAS (Table 1). The skin section of the MITAX and the CAT activity scores were significantly correlated with the physician’s skin VAS. DAS skin, MITAX skin and CAT Activity scores were all negatively correlated with CMAS and MMT8 scores; no significant correlations were noted with the CK. DAS skin scores were significantly correlated with both the CRP and ESR, while the MITAX skin was significantly correlated only with the ESR, and CAT Activity only with the CRP.

Table 1 – Spearman’s correlation between items shown as rs and corresponding p value

 

Skin VAS n=67

CMAS

n=67

MMT8

n=67

CK

n=52

CRP

n=55

ESR

n=54

DAS skin

rs   0.795 p<0.001

rs   -0.443

p<0.001

rs   -0.424

p<0.001

rs   0.176

p 0.212

rs   0.280

p 0.039

rs   0.311

p 0.022

MITAX skin

rs 0.594 p<0.001

rs -0.404

p 0.001

rs -0.453

p<0.001

rs 0.177

p 0.210

rs 0.208

p 0.127

rs 0.281

p 0.040

CAT Activity

rs 0.623 p<0.001

rs -0.471

p<0.001

rs -0.428

p<0.001

rs 0.157

p 0.267

rs 0.300

p 0.026

rs 0.164

p 0.235

Conclusion: These data demonstrate the potential application of using a skin assessment tool to evaluate and monitor skin involvement in JDM patients. It also demonstrates that the DAS skin section appears to be the best of the tools using the physician’s skin VAS as the gold standard. The DAS skin tool was concise, quick to use and easy to score.


Disclosure:

R. Campanilho-Marques,
None;

B. Almeida,
None;

K. Arnold,
None;

K. Nistala,
None;

C. A Pilkington,
None;

L. R. Wedderburn,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-the-utility-and-validity-of-three-scoring-tools-to-detect-skin-disease-in-patients-with-juvenile-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology